Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-01-15 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第二届董事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 28th meeting of the second board of directors of Shenzhen BGI Genomics Co., Ltd. It details the meeting date, attendance, voting results, and specific agenda items such as approval of related party transactions for 2021. There is no financial data, earnings information, or detailed report content. The document is clearly a board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length is short (1122 characters), and it is not an announcement of a report publication but a direct disclosure of board decisions.
2021-01-15 Chinese
关于2021年度拟与关联方进行日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Co., Ltd. regarding its proposed daily related-party transactions for the year 2021. It includes extensive information about the nature, amounts, counterparties, pricing policies, and approvals related to these related-party transactions. The document references the board meeting resolutions, independent directors' opinions, and supervisory board review, all typical for disclosures about related-party transactions. There is no indication that this is a full financial report, audit report, earnings release, or other types of filings. Instead, it is a regulatory announcement about related-party transactions, which is a common type of regulatory filing in Chinese stock exchanges. The document length is about 9,675 characters, which is substantial but not a full annual or interim report. It does not contain financial statements or comprehensive financial analysis but focuses on the related-party transaction details and approvals. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-15 Chinese
关于全资子公司医疗器械产品延续注册的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding the renewal of medical device registrations for COVID-19 nucleic acid testing products by its wholly-owned subsidiary. It includes details about the registration certificates, product descriptions, and the impact and risk warnings related to these registrations. The document is relatively short (1871 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an announcement about regulatory approval and product registration status rather than a financial report or management update. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-01-14 Chinese
独立董事关于第二届董事会第二十七次会议相关事项的独立意见
Capital/Financing Update Classification · 95% confidence The document is an independent opinion from independent directors regarding the authorization for a private placement of shares (向特定对象发行股票) by the company Shenzhen BGI Genomics Co., Ltd. It references regulatory approvals and compliance with relevant laws and company articles. The content focuses on the authorization and opinion related to a capital raising activity through a private share issuance. The document length is short (765 characters) and it is not a full report but an opinion statement related to a capital/financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-01-05 Chinese
第二届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a specific board meeting of Shenzhen BGI Genomics Co., Ltd. It details the convening of the board meeting, the voting results on various proposals including stock issuance authorization, opening of special accounts for raised funds, and a self-inspection report on corporate governance. The document is titled as a 'Board of Directors Meeting Resolution Announcement' and includes procedural details and voting outcomes. It does not contain financial statements, earnings data, or detailed management discussion but focuses on board decisions and governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is 2406 characters, which is consistent with an announcement rather than a full report.
2021-01-05 Chinese
中信证券股份有限公司关于公司2020年持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2020年持续督导现场检查报告" which translates to "2020 Continuous Supervision On-site Inspection Report" by CITIC Securities for Shenzhen BGI Genomics Co., Ltd. It details the on-site inspection findings related to corporate governance, internal controls, information disclosure, use of raised funds, performance, and compliance issues for the year 2020. The content includes detailed audit-like procedures, compliance checks, and corrective measures, but it is not a full annual report or financial statement. It is a standalone audit or inspection report focusing on governance, compliance, and internal controls rather than a full financial performance report. The document length is over 5,000 characters and contains substantive content, not just an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2020
2020-12-31 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.